A PYMNTS Company

US: Countersuit is latest in genetics patent spat

By  |  August 6, 2013

In response to a lawsuit filed by Myriad Geneics against rival Ambry Genetics accusing Ambry of patent infringement, Ambry has filed its own countersuit against its competitor for alleged antitrust violations. Reports say Ambry filed its own lawsuit in California on Tuesday, alleging Myriad’s initial claim violated antitrust law and “are invalid under two Supreme Court decisions and Federal Circuit authority.” The Supreme Court ruled last month that Myriad cannot hold patents on certain gene sequences. Myriad soon after filed a lawsuit claiming a testing process used by Ambry for detecting mutations in such gene sequences violated Myriad’s patent; Myriad claims that despite the Supreme Court ruling, it still holds valid claims in 24 patents.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: Genome Web

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.